Loading...
XNYSQGEN
Market cap9.91bUSD
Dec 20, Last price  
44.67USD
1D
0.79%
1Q
-0.51%
Jan 2017
59.42%
Name

Qiagen NV

Chart & Performance

D1W1MN
XNYS:QGEN chart
P/E
29.04
P/S
5.04
EPS
1.54
Div Yield, %
0.00%
Shrs. gr., 5y
-0.85%
Rev. gr., 5y
5.53%
Revenues
1.97b
-8.23%
380,629,000398,395,000465,778,000649,774,000892,975,0001,009,825,0001,087,431,0001,169,747,0001,254,456,0001,301,984,0001,344,777,0001,280,986,0001,337,991,0001,417,536,0001,501,848,0001,526,424,0001,870,346,0002,251,657,0002,141,518,0001,965,311,000
Net income
341m
-19.35%
48,705,00062,225,00070,539,00050,122,00089,033,000137,767,000144,311,00096,038,000129,506,00069,073,000116,634,000127,103,00080,404,00040,394,000190,380,000-41,455,00073,640,000512,599,000423,211,000341,303,000
CFO
459m
-35.76%
53,798,00091,237,000101,479,00084,811,000172,998,000216,995,000250,752,000244,779,000244,880,000258,957,000287,965,000317,497,000341,602,000286,779,000359,496,000330,843,000492,272,000639,001,000715,264,000459,455,000
Earnings
Jun 20, 2025

Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
IPO date
Sep 01, 1996
Employees
6,100
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,965,311
-8.23%
2,141,518
-4.89%
2,251,657
20.39%
Cost of revenue
1,520,064
1,550,759
1,575,269
Unusual Expense (Income)
NOPBT
445,247
590,759
676,388
NOPBT Margin
22.66%
27.59%
30.04%
Operating Taxes
88,506
89,390
113,234
Tax Rate
19.88%
15.13%
16.74%
NOPAT
356,741
501,369
563,154
Net income
341,303
-19.35%
423,211
-17.44%
512,599
596.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
163
(25,235)
(92,068)
BB yield
0.00%
0.23%
0.74%
Debt
Debt current
610,238
389,552
847,626
Long-term debt
1,079,950
1,494,118
1,116,192
Deferred revenue
15,244
191,879
Other long-term liabilities
227,246
341,949
209,320
Net debt
602,923
441,858
708,087
Cash flow
Cash from operating activities
459,455
715,264
639,001
CAPEX
(162,802)
(149,336)
(206,534)
Cash from investing activities
(87,655)
(726,763)
(202,426)
Cash from financing activities
(433,827)
(125,803)
(150,366)
FCF
(93,849)
461,124
444,594
Balance
Cash
1,057,782
1,418,266
1,065,301
Long term investments
29,483
23,546
190,430
Excess cash
988,999
1,334,736
1,143,148
Stockholders' equity
2,025,672
1,758,784
1,141,102
Invested Capital
4,657,136
4,336,538
4,270,748
ROIC
7.93%
11.65%
12.42%
ROCE
7.89%
10.38%
12.41%
EV
Common stock shares outstanding
223,700
223,232
225,073
Price
43.43
-12.91%
49.87
-10.27%
55.58
5.17%
Market cap
9,715,308
-12.73%
11,132,574
-11.01%
12,509,554
4.19%
EV
10,318,231
11,574,432
13,217,641
EBITDA
650,583
799,156
891,319
EV/EBITDA
15.86
14.48
14.83
Interest
53,410
58,357
54,477
Interest/NOPBT
12.00%
9.88%
8.05%